Goldman Sachs
May 14, 2026
Sysmex Earnings Review Results In Line
Single Stock ReportEquitiesHealth Care
Sysmex's FY3/26 results met expectations on an underlying basis, but FY3/27 guidance missed consensus due to risks in China and inflation. Goldman Sachs maintains a Buy rating with a reduced target price of ¥1,700.
Key Takeaways
- 1.FY3/26 results were broadly in line with expectations, excluding a one-time impairment loss.
- 2.FY3/27 operating profit guidance is below consensus due to price pressure in China and rising SG&A costs.
- 3.Goldman Sachs maintains a Buy rating but has lowered the 12-month target price to ¥1,700.
Table of Contents
- Earnings overview and GSe revisions
- GS Forecast
- GS Factor Profile
- Ratios & Valuation
- Growth & Margins (%)
- Price Performance
- Income Statement (¥ bn)
- Balance Sheet (¥ bn)
- Cash Flow (¥ bn)
- Price Target Risks and Methodology - Sysmex
- Investment Thesis - Sysmex
- Disclosure Appendix
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Akinori Ueda, Ph.D.Tomo Taniguchi
Securities
Sysmex
Themes
China Market DeteriorationInflationary Cost PressuresMedical Diagnostics Innovation
Regions
Asia PacificEuropeNorth AmericaJapanChinaUnited States
